Tega Industries Q1 FY27 Results Analysis: Normalized PAT Jumps 158%, Molycop Debut Above Guidance

Cofacto Research Updated August 14, 2026 2 min read
Positive

Tega Industries Ltd's Q1 FY27 numbers came in strong. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 13, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 1,723.44 Cr (+383.99% YoY)
PAT (Q1)Rs. -108.25 Cr
EBITDA margin14.30% (-131 bps YoY)
EPS (Q1)Rs. -11.47
Market capRs. 12,542.57 Cr
CMPRs. 1,669.50

Quarter Snapshot

Strong standalone performance with 60% revenue growth and margin expansion, plus an above-guidance Molycop debut, confirm the core thesis. The reported loss is entirely due to one-time acquisition costs; normalized PAT rose 158% YoY. Equipment segment weakness and elevated finance costs are near-term concerns, but underlying profitability and order conversion remain healthy.

Key Investment Insights

Key Positives

  • Standalone revenue grew 60.30% YoY to Rs.268.65 Cr, with EBITDA margin expanding 538 bps to 26.43% (above 21-22% guidance)
  • Molycop contributed one-month revenue of Rs.1,291.64 Cr at 13.24% EBITDA margin (above ~12% guidance)
  • Consumables Others segment revenue grew 35.08% YoY, confirming conversion of delayed orders
  • Normalized PAT-to-owners of Rs.91.28 Cr vs Rs.35.34 Cr YoY, a 158% increase
  • Segment EBITDA of Rs.246.53 Cr (14.30% margin) shows underlying operating profitability despite one-time costs

Risk Factors

  • Consolidated reported loss of Rs.108.25 Cr due to one-time Molycop acquisition costs of Rs.190.96 Cr
  • Equipment segment revenue fell 44.37% YoY and swung to an EBITDA loss of Rs.1.59 Cr, missing 25%+ growth guidance
  • Finance costs surged to Rs.116.71 Cr from Rs.6.18 Cr YoY (annualized ~Rs.467 Cr), driven by acquisition debt, pressuring net earnings
  • Molycop's lower-margin grinding media mix (13.24% EBITDA) combined with higher finance costs reduces overall profitability
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.

Powered by Cofacto — AI research platform for Indian stocks, every claim cited from primary filings

Login Now